NanoLogix Files International Patent Applications, Reclaims 18 Existing Patents, Noted in Department of Defense Quarterly Public
03 Noviembre 2009 - 8:45AM
Marketwired
NanoLogix, Inc. (PINKSHEETS: NNLX) announces that the company has
recently filed BNP™ (BioNanoPore) national patent applications in
China, Japan, India, Brazil, Russia and the EU. These applications
were filed in order to obtain intellectual property protection for
the company's technology in countries viewed as representing the
largest potential international market for BNP rapid detection, a
revolutionary sandwiched-membrane Petri-based technology that can
reduce microorganism detection times by 100-400%.
At the company's September 25th shareholder meeting, the support
for all proposals presented by the company for shareholder approval
was overwhelmingly positive, with all
shareholder-rights/takeover-defense plan proposals receiving 98-99%
of the 64 million shares voted out of roughly 101 million shares
outstanding.
The company has reclaimed full rights to 18 patents previously
licensed to Nutra Pharma Corporation after failure of Nutra Pharma
to pay the balance of patent royalties due for 2008 and the first
half of 2009. Nutra Pharma was served notice of their default in
July. NanoLogix has returned the 18 patents to the company
portfolio and will pursue development and marketing of select
technological aspects of the patents.
NanoLogix's April press release: "New Weapon in BioDefense
Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and
Bubonic Plague," was highlighted in the latest issue of the
Department of Defense Quarterly, "CBRNIAC," from the Chemical,
Biological, Radiological and Nuclear Defense Information Analysis
Center. The publication can be accessed at:
https://www.cbrniac.apgea.army.mil/Products/Newsletter/Pages/default.aspx
NanoLogix has received notification from New Brunswick
Scientific of a November 20th shipping date for ordered production
equipment for its cleanroom production facility at the company's
Hubbard, Ohio headquarters. This order consists of four machines
for production of BNP rapid-detection kits and is anticipated to be
the first of many for kit production.
NanoLogix management, staff, and directors would like to
congratulate Corporate Counsel David R. Barnhizer for his recent
three-year appointment as Visiting Professor to the University of
Westminster, London. Professor Barnhizer will continue as corporate
counsel.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on
medical diagnostics. Its products offer accelerated detection and
identification of microorganisms present in infectious and
non-infectious human diseases. In addition to medical, National
Defense, and Homeland Security applications, NanoLogix technology
is applicable in pharmaceutical, industrial, veterinary and
environmental testing.
Patents pending or granted to NanoLogix can be used in the areas
of applied microbiology, soil microbiology and bioremediation,
microbial physiology, molecular biology, pharmacology,
pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and
bioreactor-based hydrogen generation.
More information on NanoLogix is available at:
www.nanologix.com
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
Contact: NanoLogix, Inc. Investor Relations Carol Surrena
Telephone: 330-534-0800 E-mail: Email Contact
NanoLogix (CE) (USOTC:NNLX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
NanoLogix (CE) (USOTC:NNLX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024